Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 9,071 shares, a drop of 54.0% from the January 29th total of 19,720 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 43,146 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 43,146 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PHAR. Weiss Ratings reissued a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. Zacks Research cut shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Pharming Group has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Hedge Funds Weigh In On Pharming Group

Large investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC increased its stake in shares of Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares in the last quarter. Millennium Management LLC bought a new position in Pharming Group in the 4th quarter worth $360,000. SmartHarvest Portfolios LLC purchased a new stake in Pharming Group in the 4th quarter worth $224,000. Finally, EverSource Wealth Advisors LLC bought a new stake in Pharming Group during the second quarter valued at about $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Stock Performance

PHAR traded down $0.07 during midday trading on Friday, reaching $16.30. The company had a trading volume of 10,117 shares, compared to its average volume of 32,743. The business has a 50-day moving average of $17.58 and a two-hundred day moving average of $15.89. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. Pharming Group has a 1 year low of $7.50 and a 1 year high of $21.34. The company has a market cap of $1.14 billion, a P/E ratio of -1,628.37 and a beta of 0.04.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.